• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

NuraLogix Unveils Telehealth Platform Performing Continuous Health/Vital Signs During Video Calls

Share:

January 9, 2023

What You Should Know:

– NuraLogix, global pioneers of contactless health monitoring whose technology can take over 30 medical-grade health vitals using any video-enabled device, unveils Anura™ Telehealth, a platform that performs continuous health and vital sign measurements while on a video call.

– This is the latest addition to its AnuraTM platform that uses conventional video cameras to extract facial blood flow information to accurately calculate a host of medical vitals and health risk assessments using numerous consumer devices in the hands of billions of people.

Using Facial Blood Flow Patterns To Unlock a Wealth of Health Data During Telemedicine Consultations

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Anura™ is the only video-based contactless health monitoring solution that can measure vital signs and provide health risk assessments. Unlike smartwatches, health trackers, and rings that track blood flow through light sensors, Anura™ can do so with a video selfie.

Anura™ is powered by NuraLogix’s patented Transdermal Optical Imaging (TOI™) technology, a novel form of Remote Photoplethysmography (rPPG). It automatically detects a person’s face, identifies key regions of interest, and extracts blood flow information that is combined with powerful AI data models developed from more than 40,000 patients with multiple health conditions.

Results are delivered within its intuitive app, showing information on over 30 health parameters such as heart rate, breathing rate, and cuffless blood pressure, and providing health risk assessments for some of the most prevalent chronic conditions. This includes type 2 diabetes, hypertension, cardiovascular disease, and mental health.

Anura™ Telehealth brings this technology into platforms to enhance remote patient monitoring and telemedicine, making them more valuable to both patients and healthcare professionals. The desktop-based platform performs continuous health and vital sign measurements while on a video call, including heart rate and cuffless blood pressure.  It provides richer interaction and appointments between patients and healthcare practitioners with the ability to provide real-time information and assist physicians in identifying future health risks.

It is designed for use in the telemedicine, remote patient management, and insurance industries. Key features of the platform include:

• Continuous real-time vital sign measurement

• Ability to integrate with video conference software such as Zoom

• Ability to integrate with telehealth software such as Doxy.me

• Customizable interfaces, templates, and reporting to accommodate different use cases

“Post-pandemic telemedicine has increasingly become the norm. While convenient and cost-effective, remote visits have until now lacked the ability for health professionals to carry out the routine health checks they would normally perform in the clinical setting,” said Dr. Keith Thompson, Chief Medical Officer at NuraLogix. “From heart rate to blood pressure, Anura™ allows this to occur in real-time while also helping physicians to leverage the power of AI and its potential to help identity, predict and prevent chronic and acute diseases.”

The ability to carry out risk health assessment is a game changer and a welcome assistance to medical professionals. Uniquely, Anura™ can assess HbA1c, monitor fasting glucose, and assess the risk of Type 2 diabetes, hypertension, and hypertriglyceridemia. Its research models have currently appeared in 10 global peer-reviewed research publications, with three additional publications in progress covering topics of hypertension, multi-year cardiovascular risk, diabetes, and fatty liver disease.  Its latest released models have been proven to predict whether a subject’s HbA1c is greater than 5.7% or their Fasting Blood Glucose is greater than 5.5mmol/L to a clinically accurate level.

NuraLogix’s Anura™ includes capabilities for investigational use and go-to-market solutions to allow and is used by customers such as NTT Data, Bupa Group, HSBC, AIA, and FWD to power health programs for consumers. Its capabilities include:

Source: Hit Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Enterprise Therapeutics’ First-in-class TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired By RocheEnterprise Therapeutics’ First-in-class TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired By Roche
  • GoodRx Closes First Year as a Public Company in Q4 2020 Earnings CallGoodRx Closes First Year as a Public Company in Q4 2020 Earnings Call
  • Expedeon AG signs EUR 120 million deal with Abcam for the sale of its immunology and proteomicsExpedeon AG signs EUR 120 million deal with Abcam for the sale of its immunology and proteomics
  • Mylan Stock Jumps On Rumored Bid After Lackluster First QuarterMylan Stock Jumps On Rumored Bid After Lackluster First Quarter
  • NHS Wales Launches ‘Caring’ AI Virtual Agent Using IBM WatsonNHS Wales Launches ‘Caring’ AI Virtual Agent Using IBM Watson
  • AWS and Pfizer Accelerate Drug Development and Clinical ManufacturingAWS and Pfizer Accelerate Drug Development and Clinical Manufacturing
  • Q/A: UnitedHealthcare Executive Talks Investment in Telehealth InnovationQ/A: UnitedHealthcare Executive Talks Investment in Telehealth Innovation
  • Aralez Pharmaceuticals To Enter Into Purchase Agreements To Sell Substantially All AssetsAralez Pharmaceuticals To Enter Into Purchase Agreements To Sell Substantially All Assets

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications